Niagen Bioscience, Inc.
Close on Oct 19, 2026
- Market cap
- $206.26M
- P/E (TTM)
- 13.9
- Dividend yield
- –
About Niagen Bioscience
Medicinal Chemicals & Botanical Products, SIC 2833
Niagen Bioscience, Inc. is a global bioscience company dedicated to healthy aging through research and commercialization of nicotinamide adenine dinucleotide (NAD+) precursors. Its business includes consumer products, ingredients, analytical reference standards and services, and a pre-revenue pharmaceutical development segment. The consumer segment markets dietary supplements under the Tru Niagen brand directly to consumers online, through retail marketplaces, and via distribution partners. Its ingredients segment supplies proprietary food-grade Niagen (nicotinamide riboside chloride) to consumer product manufacturers and pharmaceutical-grade Niagen to FDA-registered 503B outsourcing facilities and compounding pharmacies for prescription injectables.
The company manufactures finished consumer goods through third-party FDA-registered facilities in the United States and maintains a research and development laboratory in Longmont, Colorado. Through strategic distribution partnerships, the enterprise markets its consumer dietary products across more than 100 countries, with commercial ingredient and supplement distribution spanning North America, Europe, the Middle East, and the Asia-Pacific region.
Summary of the business section of Niagen Bioscience's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Niagen Bioscience, Inc.
- Founded
- 1999
- Headquarters
- Los Angeles, CA
- Address
- 10900 Wilshire Blvd, Suite 600 90024
- Phone
- (310) 388-6706
- Website
- truniagen.com
- Employees
- 117, Dec 31, 2025
- Industry
- Medicinal Chemicals & Botanical Products
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Crowe LLP, Costa Mesa, California
Stock & identifiers
- Ticker
- NAGE
- Exchange
- Nasdaq
- Shares outstanding
- 79M, Jul 30, 2026
- Public float
- $813.90M, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 1-for-3 reverse, May 12, 2016; 1-for-3 reverse, Apr 13, 2016
- SEC CIK
- 1386570
- CUSIP
- 171077407
- ISIN
- US1710774076
- LEI
- 529900OPI7B8JPXCVS70
- EIN
- 26-2940963
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Robert N. Fried | Chief Executive Officer, Director | 1,667,834 |
| Carlos Luis Lopez | SVP, General Counsel | 4,565 |
| Ozan Pamir | Chief Financial Officer | 13,848 |
| Wing Tak Wendy YU | Director | – |
| Wang Yu Gary Ng | Director | – |
| Ann Cohen | Director | – |
| Steven D. Rubin | Director | 7,000 |
| Hamed Shahbazi | Director | – |
| Kristin Patrick | Director | 3,000 |
| Frank L. Jaksch Jr | Director | 2,319,231 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Robert Fried | $8.38M | $10.28M | $637.24K | $133 | $148 |
| FY2024 Robert Fried | $1.21M | $2.99M | $408.68K | $111 | $117 |
| FY2023 Robert Fried | $1.16M | $1.03M | $691.59K | $30 | $113 |
| FY2022 Robert Fried | $1.16M | $843.38K | $721.43K | $35 | $113 |
| FY2021 Robert Fried | $1.10M | $2.10M | $786.26K | $78 | $111 |
| FY2020 Robert Fried | $1.13M | $1.31M | $719.11K | $111 | $113 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, Niagen Bioscience had 117 full-time employees, none of whom were represented by a labor union.”
Corporate history
Events identified from SEC filings